<DOC>
<DOCNO>EP-0635496</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Benzospiroalkene derivatives, process for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P902	C07D49500	A61K314184	A61K314188	A61P2528	A61P2500	C07D49510	A61P4300	A61P2500	C07D23502	A61K314164	A61K31415	A61P4300	C07D23500	A61P900	C07D491107	A61K31415	A61P2520	C07D49100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07D	A61K	A61K	A61P	A61P	C07D	A61P	A61P	C07D	A61K	A61K	A61P	C07D	A61P	C07D	A61K	A61P	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P9	C07D495	A61K31	A61K31	A61P25	A61P25	C07D495	A61P43	A61P25	C07D235	A61K31	A61K31	A61P43	C07D235	A61P9	C07D491	A61K31	A61P25	C07D491	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I): 
<
IMAGE
>
  in which:   - X represents -CH2-, -(CH2)2-, -CH=CH-, -O-CH2-, S-CH2-, -SO-CH2- or -SO2-CH2-, - R1 represents a hydrogen or halogen atom or a linear or branched (C1-C6)alkoxy group, - R2 represents a linear or branched (C1-C6)alkoxy or a linear or branched (C1-C6)alkylthio group, their isomers and their addition salts with a pharmaceutically acceptable acid. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I):


wherein:

- X
represents -CH
2
-, -(CH
2
)
2
-, -CH=CH-, -O-CH
2
-, -S-CH
2
-, -SO-CH
2
- or
-SO
2
-CH
2
-,
- R
1
represents a hydrogen or halogen atom or a linear or branched (C
1
-C
6
)alkoxy
group,
- R
2
represents a linear or branched (C
1
-C
6
)alkoxy or linear or branched (C
1
-C
6
)alkylthio
group,

their isomers, and also addition salts thereof with a pharmaceutically acceptable acid.
Compounds of formula (I) according to claim 1 wherein X represents -(CH
2
)
2
-,
their isomers, and also addition salts thereof with a pharmaceutically acceptable acid.
Compound of formula (I) according to claim 1 which is spiro[(1,3-diazacyclopent-1-ene-5
: 2'-(5',8'-dimethoxy-1',2',3',4'-tetrahydronaphthalene)]
, its isomers, and
also addition salts thereof with a pharmaceutically acceptable acid.
Process for the preparation of compounds of formula (I) according to claim 1,
characterised in that there is used as starting material a compound of formula (II):


 
wherein X, R
1
 and R
2
 are as defined for formula (I)

which is reacted 
either
 with:

benzylamine in the presence of 
para
-toluenesulphonic acid to yield a compound of
formula (III):



wherein X, R
1
 and R
2
 are as defined for formula (I)

which is reacted, under an inert atmosphere, with trimethylsilyl cyanide in the
presence of zinc iodide,

to yield a compound of formula (IV):


wherein X, R
1
 and R
2
 are as defined for formula (I),

which is reduced using lithium aluminum hydride, then by catalytic hydrogenation to
yield a compound of formula (V):


 
wherein X, R
1
 and R
2
 are as defined for formula (I),
or
 with
potassium cyanide in the presence of ammonium chloride in an inert medium or with
sodium cyanide in an acid medium, or with trimethylsilyl cyanide in the presence of

zinc iodide and then with an alcoholic solution saturated by ammonia,
to yield a compound of formula (VI):



wherein X, R
1
 and R
2
 are as defined for formula (I),

which is reduced using lithium aluminium hydride to yield a compound of formula (V)
defined above,

which compound of formula (V) is reacted with formamidine in an alcoholic medium or
with an alkyl formate,

to yield a compound of formula (I)

which is purified, where appropriate, in accordance with a conventional purification
method,

separated, if desired, into its isomers in accordance with a conventional purification
method,

and transformed, optionally, into addition salts thereof with a pharmaceutically
acceptable acid.
Pharmaceutical compositions comprising as active ingredient at least one
compound according to any one of claims 1 to 3 on its own or in combination with one

or more pharmaceutically acceptable inert non-toxic excipients or carriers.
Pharmaceutical compositions according to claim 5 comprising at least one
active ingredient according to any one of claims 1 to 3 for use as an Î±
1
-adrenergic 
agonist in the treatment of hypotension, hypersomnia, attention and memory

disorders, and also of symptoms occurring in degenerative diseases.
</CLAIMS>
</TEXT>
</DOC>
